No higher dose requirements with insulin detemir than glargine in type 2 diabetes: A crossover, double-blind, and randomized study using continuous glucose monitoring

Journal of Diabetes Science and Technology

Volumn 4, Issue 1, 2010, Pages 151-154

  King, Allen B ^a,b  

^a Diabetes Care Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Continuous glucose monitoring; Detemir; Glargine; Insulin dosing; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; INSULIN DETEMIR;

AGED; AMBULATORY MONITORING; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HUMAN; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; MONITORING, AMBULATORY;

EID: 77953020941     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400119     Document Type: Article

References (7)

1. King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with in type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11(1):69-71.
2. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basalbolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-87.
3. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trail comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-16.
4. Owens DR, Bolli GB. Beyond the era of NPH insulin - long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008;10(5):333-49.
5. Strange P. Treat-to-target titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol. 2007;1(4):540-8.
6. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31 Suppl 2:S262-8.
7. Swinnen SG, DeVries JH. Higher dose requirements with insulin detemir in type 2 diabetes - three cases and a review of the literature. Diabetes Res Clin Pract. 2009;84(2):e24-6.